KIT and chronic myelogenous leukemia, BCR-ABL1 positive: As an illustration, the efficiency of GleevecTM to treat chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST) is a consequence of its capacity to bind to and stabilize the inactive form of KIT and its binding preferences are governed by conformational selection [83].